Wire · opportunities
Eli Lilly offers new weight loss drug to some patients before FDA approval
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 7 August 2026 · Fusion42 review
Eli Lilly is offering limited early access to retatrutide, a next-generation triple agonist weight loss drug, to specific patients before FDA approval. The drug has shown significant weight loss results and potential benefits for osteoarthritis pain but also higher side effects, with further trials planned before seeking full FDA approval.
This Wire brief sits within Fusion42's coverage of Health, and 3 sources have reported it between 3 Aug 2026 and 7 Aug 2026.
◆ ◆ The Wire takeaway
You now have a rare window to engage patients qualifying for Eli Lilly’s early access program before FDA approval tightens market competition. This move shifts the obesity treatment market, opening a new route for patient acquisition and clinical data gathering.
◆ Coverage
3 sources · first reported 3 Aug 2026 · latest 7 Aug 2026
◆ Related on Wire
◆ Topics